Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market?

03 medical and health sciences 0302 clinical medicine 3. Good health
DOI: 10.2337/diaclin.30.4.138 Publication Date: 2012-10-15T20:29:59Z
ABSTRACT
IN BRIEF Biosimilar insulins are likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulins have the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes. However, they will have to overcome numerous regulatory hurdles, meet a variety of commercial demands, and effectively confront competition from both established and next-generation branded insulin products before they can succeed on the global market.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (86)
CITATIONS (50)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....